POS0321 USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT

Background: Hydroxychloroquine (HCQ) is a well-tolerated drug that contributes to downregulating the immune response against autoantigens and it has been used in several autoimmune diseases. In systemic sclerosis (SSc) treat inflammatory arthritis without proof of efficacy. Objectives: Our aim was evaluate use HCQ its impact on Health Assessment Questionnaire disability index (HAQ-DI) Cochin Hand Function Status (CHFS). large SSc cohort compared propensity matched group patients not using HCQ. Methods: from European Scleroderma Trials Research (EUSTAR) data base treated with for at least 6 months were evaluated. Demographic clinical data, concomitant drugs, duration treatment reasons discontinuation, HAQ-DI CHFS (at 2 evaluation) recorded outcome variables interest. Statistical analysis performed score matching age, gender, disease duration, corticosteroids, immunosuppressives, vasoactive DMARDs 3:1 control:HCQ ratio. Standard descriptive statistics Student’s t-test Chi-square test assess propensity-matched groups. Results: 1,636 17,805 (9.2%) months; out these 3% (50/1636). had baseline follow-up evaluation, (and 44/1636 (2.7%) evaluation. Propensity assured pts demographic such as gender (mean vs no HCQ:femals:92.0 85.3), age(49.8 49.97yrs) duration(8.3 9.1 yrs), limited disease(55.3 62.6%) well background medications (P>0.1-0.9). We did find any significant changes HAQ or (difference slope) over 365 days treatment, comparing HCQ-treated non-HCQ (p=0.240 both (Figure 1). Conclusion: Results EUSTAR registry showed by 9.2% patients. improve CHFS, users users. Disclosure Interests: Silvia Bellando Randone: None declared, Holly Wilhalme: Cosimo Bruni: Elise Siegert: Paolo Airò: Rosaria Irace: Oliver Distler: Andrea Doria: Lidia P. Ananieva: László Czirják: Christopher Denton: Yannick Allanore: Valeria Riccieri: ALESSANDRA VACCA: Ivan Foeldvari Consultant of: Gilead, Novartis, Pfizer, Hexal, BMS, Sanofi, MEDAC, Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Lilly Medscape, Bayer, ARXX, Grant/research support from: Armando Gabrielli: Marco Matucci-Cerinic: Daniel Furst: declared